Peptide Knowledge Base · Recovery

PEG-MGF / MGF: what it is, what the evidence says, and its real status

A local-repair splice variant of IGF-1 from the same performance corner as IGF-1 LR3.

Can you actually get it?

Plain-English verdict: Education only.

Regulatory status: Expected to stay restricted.

How does PEG-MGF / MGF work?

A pegylated mechano-growth-factor (an IGF-1 splice variant) proposed to drive local muscle-fiber repair and proliferation.

What it does — and what it does not do

What it does: Studied for localized muscle repair signaling.

What it does not do: It is not characterized for human safety.

How honest is the evidence?

Evidence grade D — Animal and lab evidence; human trials still to come.

research-only; minimal human data

A grade measures how much human evidence exists, not whether a molecule is good, safe, or worth your interest. Read our grading methodology for what each grade means.

What we still don't know: Human evidence is minimal; growth-signaling safety is uncharacterized.

WADA status: Banned (S2).

Who should not take it

WADA S2 banned; growth-signaling risk; not characterized for human use.

Sources

Mechano-growth-factor / IGF-1 splice-variant literature; FDA compounding restriction list

Compounded medications are not FDA-approved. We keep two signals separate and never collapse them: whether you can get something, and what the rule currently says. See the live FDA Peptide Tracker for status.

Join the founding list →

Embed this card on your site · free, CC BY 4.0, no key.

Last reviewed Jun 18, 2026 · Peptós.LIFE · Not medical advice.